SCHEDULE 13D: Activist Investor Kent Lake Partners Opposes Quanterix-Akoya Merger, Citing 'Value Destruction' and Undervaluation

Activist investor Kent Lake Partners, holding a 5.91% stake in Quanterix Corp, has publicly opposed the company's proposed stock merger with Akoya Biosciences, calling it a 'bailout' that significantly undervalues Quanterix and risks its financial stability.

Summary

• Kent Lake Partners LP, Kent Lake PR LLC, and Benjamin Natter (collectively, the "Reporting Persons") have filed a Schedule 13D, disclosing beneficial ownership of 2,277,954 shares of Quanterix Corp (QTRX) common stock, representing approximately 5.91% of the outstanding shares.
• The Reporting Persons acquired these shares with working capital, totaling approximately $21,676,855, based on their belief that Quanterix shares were undervalued and represented an attractive investment opportunity.
• The primary purpose of this filing is to express vehement opposition to Quanterix's proposed acquisition of Akoya Biosciences, Inc. (AKYA), which they detail in a letter to stockholders dated February 13, 2025.
• Kent Lake asserts that the merger terms are 'indefensible,' valuing the 'superior' Quanterix business at an implied Total Enterprise Value (TEV) of $42 million, while the 'inferior' Akoya business is valued at $168 million TEV, or 4x higher.
• They argue the merger is a 'bailout' of Akoya shareholders at the expense of Quanterix shareholders, leading to significant dilution (over 40% increase in QTRX share count) and a dramatic reduction in Quanterix's cash reserves.
• Kent Lake urges the Quanterix Board to abandon the merger, pay the modest breakup fee, and refocus on Quanterix's organic growth opportunities, particularly the transformational Alzheimer's testing opportunity.
• The Reporting Persons are prepared to mobilize shareholders to vote against the deal and nominate directors for the Quanterix Board at the 2025 Annual Meeting if the Board insists on pursuing the merger.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative regarding the proposed merger, with strong language used to describe it as 'value destructive,' 'indefensible,' and a 'bailout.' The document expresses deep concern over the financial implications and strategic misdirection, though it maintains a positive outlook on Quanterix's standalone potential.

Positives

• Quanterix is described as having a 'unique highly sensitive blood-based proteomics platform' and a 'transformational clinical Alzheimer's blood testing opportunity'.
• Quanterix's standalone business is characterized by 'highly recurring and double-digit growth research and translational use business'.
• Quanterix is stated to have a 'fortress balance sheet with a clear path to profitability without needing to raise capital' as a standalone entity.
• Quanterix has higher revenue, double-digit revenue growth, higher GAAP gross margins, and higher cash flow margins compared to Akoya.
• Quanterix's clinical diagnostic market opportunity in Alzheimer's testing ($9 billion per Leerink Partners) is significantly larger than Akoya's CDX opportunity.

Negatives

• The proposed QTRX-AKYA merger terms are deemed 'indefensible' and a 'bailout' of Akoya shareholders at the expense of Quanterix shareholders.
• The merger values the Quanterix business at an implied $42 million Total Enterprise Value (TEV), while the Akoya business is valued at an implied $168 million TEV, a 4x higher valuation for the 'inferior' Akoya.
• Akoya is characterized as having less revenue, burning more cash, having a significantly smaller Total Addressable Market (TAM) for its CDX opportunity, and being attached to a 'distressed balance sheet'.
• The merger is expected to grow Quanterix's share count by over 40% and significantly reduce its cash balance.
• The transaction is believed to divert critical management focus from Quanterix's promising Alzheimer's opportunity to 'chase dubious cost synergies' from Akoya.
• The combined entity's proforma cash runway shrinks dramatically to just 2.5 years, compared to Quanterix's standalone 6.5 years, increasing the risk of needing additional equity.
• Synergy projections are questioned, with concerns that Akoya's prior workforce reductions (35%) have already negatively impacted its revenue trajectory, and that a major component of 'synergies' are merely interest cost savings from paying down Akoya's debt.

Risks

• The proposed merger carries the risk of being dilutive to Quanterix shareholders, both economically and in terms of management focus.
• Diverting management focus to the merger could cause Quanterix to miss the 'transformational Alzheimer's opportunity' which requires FDA approval, ADLT reimbursement, and scaling revenue without increasing cash burn.
• The merger substantially increases the risk that Quanterix will need to raise additional equity, particularly as it scales its Alzheimer's clinical diagnostic initiatives.
• There is a risk that pro-forma synergy and cash flow breakeven targets could be missed, potentially forcing Quanterix to raise capital through equity dilution or high-cost debt.
• Akoya's previous workforce reductions (approximately 35%) have already had a 'deleterious impact' on its revenue trajectory, suggesting future synergy capture activities risk precipitating further revenue declines for the combined entity.
• The life science tools industry is under pressure due to proposed NIH funding cuts under the Trump administration and an evolving trade war with China, adding to financial risks.

Future Outlook

The Reporting Persons intend to continuously review their investment in Quanterix. Depending on market conditions, investment opportunities, and share prices, they may increase or decrease their position. They plan to engage in communications with Quanterix management and Board, discuss with other stockholders, and potentially make recommendations regarding capitalization, ownership, board structure, business combinations, or operational performance. They are prepared to mobilize shareholders to vote against the proposed merger and nominate directors for the Quanterix Board at the 2025 Annual Meeting if the merger proceeds. Kent Lake believes Quanterix's share price will increase substantially if the merger agreement is terminated, and that the company should focus on its organic growth opportunities, particularly the Alzheimer's testing market, or explore a sale at a valuation exceeding $1 billion.

Management Comments

• "Kent Lake is vehemently opposed to QTRX Board's recommendation to do a stock merger that is effectively a bail out of struggling and in our view inferior peer Akoya Biosciences (AKYA) at a significant valuation premium compared to that accorded to QTRX shareholders in the merger."
• "Kent Lake believes this proposed merger is a BAILOUT of Akoya Shareholders at the expense of Quanterix Shareholders and that QTRX SHAREHOLDERS MUST VOTE AGAINST this transaction."
• "Kent Lake believes that investment bankers hoodwinked the QTRX management team and Board into this highly value destructive transaction, because, well they are bankers. But ultimately the fiduciary responsibility lies with Quanterix Board for agreeing to this value destruction."
• "Kent Lake believes the Quanterix Board has breached their fiduciary duties to shareholders with their vapid logic around this deal."
• "This is a terrible deal that grows QTRX share count by over 40% and significantly reduces our cash in order to acquire struggling, inferior AKYA!"
• "While Quanterix management wastes time squeezing blood from the proverbial Akoya stone an organization that has already gone through multiple restructurings in the past 12 months they risk missing the transformational Alzheimer's opportunity."
• "Board members have an obligation to also consider what happens if their Pro-forma synergy and cash flow breakeven targets are missed—likely leading to Quanterix being forced to raise capital through equity dilution or high-cost vulture debt, as Akoya has in the past."
• "Kent Lake urges the Quanterix Board of Directors to abandon this misguided merger and pay the modest breakup fee to Akoya shareholders."
• "The Board must refocus on the company’s more promising organic growth opportunities in the research market while placing particularly strong attention on the transformational Alzheimer's testing opportunity."
• "If the Board wishes to pursue strategic alternatives, they should explore the sale of Quanterix at a valuation exceeding $1 billion."

Industry Context

The announcement relates to the broader life science tools industry, which is currently facing pressures from proposed NIH funding cuts under a potential Trump administration and an evolving trade war with China. The document highlights the significant interest in proteomics platforms within the industry, citing Thermo Fisher Scientific's recent acquisition of Olink for over $3 billion as an example of strategic acquirers seeking such assets. Kent Lake positions Quanterix's Alzheimer's blood testing opportunity as a major potential growth driver within the clinical diagnostics sector, contrasting it with Akoya's spatial technology and smaller clinical diagnostic market opportunity.

Comparison to Industry Standards

• Kent Lake directly compares Quanterix's implied enterprise value of $42 million in the merger to Akoya's implied enterprise value of $168 million, stating Akoya's valuation is 4x higher despite Quanterix having 67% more revenue, double-digit revenue growth (while Akoya's declined 15% in 2024), higher GAAP gross margins, and higher cash flow margins.
• Quanterix's business model is noted for higher recurring revenues compared to Akoya's 'volatile capital sales model'.
• Quanterix's clinical diagnostic market opportunity in Alzheimer's testing is estimated at $9 billion (per Leerink Partners), which 'dwarfs' Akoya's CDX opportunity with Acrivon Therapeutics (a $200 million market cap, zero revenue company).
• The document references Thermo Fisher Scientific's acquisition of Olink (formerly OLK) for over $3 billion as an example of a major industry player demonstrating strong interest in proteomics platforms, suggesting Quanterix could command a significant premium from similar strategic acquirers.

Stakeholder Impact

• Shareholders: Potential for significant dilution and value destruction if the merger proceeds, but potential for substantial share price increase if the merger is terminated and Quanterix focuses on its standalone opportunities or is sold at a premium.
• Management: Risk of diverted focus from core strategic initiatives (e.g., Alzheimer's diagnostics) to integration efforts for a potentially inferior acquisition.
• Employees (Akoya): Akoya has already undergone significant workforce reductions (35%), and further synergy capture could lead to more job impacts.
• Creditors (Akoya): The merger is seen as a 'bailout' for Akoya, implying a positive impact for its creditors by paying down high-cost debt.

Next Steps

• The Reporting Persons may endeavor to increase or decrease their position in Quanterix through open market purchases or sales, or private transactions.
• The Reporting Persons intend to review their investment in Quanterix on a continuing basis.
• The Reporting Persons may engage in communications with Quanterix management and the Board of Directors.
• The Reporting Persons may engage in discussions with Quanterix stockholders or other third parties about the Issuer and their investment, including potential business combinations or dispositions.
• The Reporting Persons may make recommendations or proposals to Quanterix concerning changes to capitalization, ownership structure, board structure (including composition), potential business combinations or dispositions, or suggestions for improving financial and/or operational performance.
• Kent Lake urges the Quanterix Board to abandon the proposed merger and pay the breakup fee to Akoya shareholders.
• Kent Lake encourages the Quanterix Board to refocus on the company's organic growth opportunities, particularly the Alzheimer's testing market.
• Kent Lake encourages all interested parties to make public offers for Quanterix as soon as possible, suggesting the Board explore a sale of Quanterix at a valuation exceeding $1 billion.
• If the Quanterix Board insists on pursuing the merger, Kent Lake is prepared to mobilize shareholders to vote against the deal.
• If the Quanterix Board insists on pursuing the merger, Kent Lake is prepared to nominate directors for the Quanterix Board at the 2025 Annual Meeting.

Key Dates

Recommendation

Keywords

Quanterix, Akoya Biosciences, Merger Opposition, Activist Investor, Schedule 13D, Shareholder Activism, Proteomics, Alzheimer's Diagnostics, Biotech Investment, Corporate Governance, Valuation Disparity, Cash Burn, Dilution